Trials / Recruiting
RecruitingNCT06570291
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis
A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells (AlloJoin®) Therapy for Knee Osteoarthritis.
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 520 (estimated)
- Sponsor
- Wuxi Cellular Biopharmaceutical Group Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mesenchymal Stem Cells | Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use |
| DRUG | Sodium Hyaluronate Injection | Sodium Hyaluronate administrated for intra-articular use |
Timeline
- Start date
- 2025-02-28
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2024-08-26
- Last updated
- 2025-07-16
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06570291. Inclusion in this directory is not an endorsement.